Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469409 | 0.83 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL469297 | 0.81 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL15120352 | 0.76 | POLB (0.45) | CNR2RAF1BRAFPOLB | |
| SCHEMBL2227038 | 0.75 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL1621457 | 0.73 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL15121201 | 0.72 | POLB (0.50) | CNR2RAF1BRAFPOLB | |
| SCHEMBL469315 | 0.71 | CNR2 (0.50) | CNR2CNR1RAF1BRAFPOLB | |
| SCHEMBL1784826 | 0.70 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL15121178 | 0.70 | POLB (0.68) | RAF1POLB | |
| SCHEMBL12747057 | 0.69 | ALDH1A1 (0.47) | CNR2RAF1BRAFPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595959-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-11-04 | — | — | EP | disclosed |
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| WO-2012012307-A9 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012012307-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | CNR2 1/4885CNR1 2/4885RAF1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.